AzTrials
AzTrials

Ulcerative ColitisPhase 2/3NCT02520284

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

A Phase 2/3 study testing Andecaliximab in people with Ulcerative Colitis, run by Gilead Sciences at 87 sites in 23 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The primary objectives of this study are as follows: 1) To evaluate the efficacy of andecaliximab to induce endoscopy, rectal bleeding, and stool frequency (EBS) clinical remission at Week 8 (Cohort 1); 2) To evaluate the efficacy of andecaliximab to maintain EBS clinical remission at Week 52 (Cohort 2); and 3) To… Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Ulcerative Colitis
What is being tested?
Andecaliximab
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
165 participants
Where
87 sitesin 23 countries
Study dates
Sep 2015to Nov 2016
Phase
Phase 2/3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Ulcerative Colitis (UC) confirmed on endoscopy
  • Moderately to severely active UC (Mayo Score 6-12)
  • May be receiving oral 5-aminosalicylate (ASA), oral corticosteroid, azathioprine, 6-mercaptopurine (MP), or methotrexate
  • Treatment failure with at least one of the following agents received: corticosteroids, immunomodulators, tumor necrosis factor-alpha (TNFα) antagonists, vedolizumab

Who cannot join

  • Diagnose of Crohn's disease or indeterminate colitis
  • Pregnant or lactating females
  • Any chronic medical condition (including, but not limited to cardiac or pulmonary disease, alcohol or drug abuse)
  • Exhibit severe UC / clinically significant active infection
  • History of malignancy in the last 5 years
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial locations and contacts

87 sites in 23 countries.

87 sites in 23 countries

United States33 sites
  • Study site

    Ann Arbor, Michigan

  • Study site

    Arlington, Texas

  • Study site

    Baytown, Texas

  • Study site

    Chapel Hill, North Carolina

  • Study site

    Charlotte, North Carolina

  • Study site

    Charlottesville, Virginia

  • Study site

    Chesapeake, Virginia

  • Study site

    Chicago, Illinois

  • Study site

    Dothan, Alabama

  • Study site

    Egg Harbor, New Jersey

  • Study site

    Germantown, Tennessee

  • Study site

    Hermitage, Tennessee

  • Study site

    Houston, Texas

  • Study site

    Irving, Texas

  • Study site

    Lauderdale Lakes, Florida

  • Study site

    Louisville, Kentucky

  • Study site

    Mentor, Ohio

  • Study site

    Miramar, Florida

  • Study site

    Monroe, Louisiana

  • Study site

    New York, New York

  • Study site

    Norfolk, Virginia

  • Study site

    Plymouth, Minnesota

  • Study site

    Richmond, Virginia

  • Study site

    Rochester, Ohio

  • Study site

    San Antonio, Texas

  • Study site

    Seattle, Washington

  • Study site

    Southlake, Texas

  • Study site

    St Louis, Missouri

  • Study site

    Topeka, Kansas

  • Study site

    Wauwatosa, Wisconsin

  • Study site

    Wheat Ridge, Colorado

  • Study site

    Winter Park, Florida

  • Study site

    Zephyrhills, Florida

Other trials in United States

Poland10 sites
  • Study site

    Bialystok

  • Study site

    Krakow

  • Study site

    Lublin

  • Study site

    Piaseczno

  • Study site

    Poznan

  • Study site

    Sopot

  • Study site

    Środa Wielkopolska

  • Study site

    Tychy

  • Study site

    Warsaw

  • Study site

    Wroclaw

Other trials in Poland

Ukraine5 sites
  • Study site

    Kharkiv

  • Study site

    Kyiv

  • Study site

    Lviv

  • Study site

    Odesa

  • Study site

    Vinnitsa

Other trials in Ukraine

Australia4 sites
  • Study site

    Footscray

  • Study site

    Herston

  • Study site

    Malvern

  • Study site

    Melbourne

Other trials in Australia

Russia4 sites
  • Study site

    Moscow

  • Study site

    Novosibirsk

  • Study site

    Rostov-on-Don

  • Study site

    Saint Petersburg

Other trials in Russia

Belgium3 sites
  • Study site

    Ghent

  • Study site

    Leuven

  • Study site

    Mouscron

Other trials in Belgium

Hungary3 sites
  • Study site

    Békéscsaba

  • Study site

    Budapest

  • Study site

    Debrecen

Other trials in Hungary

New Zealand3 sites
  • Study site

    Auckland

  • Study site

    Christchurch, Canterbury

  • Study site

    Wellington

Other trials in New Zealand

United Kingdom3 sites
  • Study site

    Cambridge

  • Study site

    Oxford

  • Study site

    Prescot

Other trials in United Kingdom

Canada2 sites
  • Study site

    Vaughan, Ontario

  • Study site

    Victoria, British Columbia

Other trials in Canada

Italy2 sites
  • Study site

    Rozzano

  • Study site

    San Giovanni Rotondo

Other trials in Italy

Romania2 sites
  • Study site

    Bucharest

  • Study site

    Timișoara

Other trials in Romania

South Korea2 sites
  • Study site

    Seoul

  • Study site

    Suwon

Other trials in South Korea

Switzerland2 sites
  • Study site

    Basel

  • Study site

    Bern

Other trials in Switzerland

Bulgaria1 site
  • Study site

    Pleven

Other trials in Bulgaria

Czechia1 site
  • Study site

    Hradec Králové

Other trials in Czechia

France1 site
  • Study site

    Nantes

Other trials in France

Ireland1 site
  • Study site

    Dublin, Leinster

Other trials in Ireland

Latvia1 site
  • Study site

    Daugavpils

Other trials in Latvia

Netherlands1 site
  • Study site

    Amsterdam

Other trials in Netherlands

Slovakia1 site
  • Study site

    Trenčín

Other trials in Slovakia

South Africa1 site
  • Study site

    Claremont, Western Cape

Other trials in South Africa

Taiwan1 site
  • Study site

    Taichung

Other trials in Taiwan

About this study

Official title: A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Ulcerative Colitis

The primary objectives of this study are as follows: 1) To evaluate the efficacy of andecaliximab to induce endoscopy, rectal bleeding, and stool frequency (EBS) clinical remission at Week 8 (Cohort 1); 2) To evaluate the efficacy of andecaliximab to maintain EBS clinical remission at Week 52 (Cohort 2); and 3) To evaluate the safety and tolerability of andecaliximab. The study will consist of 3 parts: Induction Phase (Cohort 1), Maintenance Phase (Cohort 2), and an optional Extended Treatment Phase.

Being tested
Andecaliximab, Placebo
Medical subject headings
Colitis, Ulcerative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AndecaliximabBiological

    Also called GS-5745

    Andecaliximab 150 mg administered via SC injection

  • PlaceboBiological

    Placebo matched to andecaliximab administered via SC injection

Study groups in NCT02520284
Study groupRoleWhat they receive
Andecaliximab Every 2 WeeksExperimentalParticipants will receive andecaliximab 150 mg administered via subcutaneous (SC) injection alternating with matching placebo weekly for a total of 4 doses of andecaliximab. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
Receives: Biological: Andecaliximab; Biological: Placebo
Andecaliximab WeeklyExperimentalParticipants will receive andecaliximab 150 mg administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
Receives: Biological: Andecaliximab
PlaceboPlacebo comparatorParticipants will receive placebo matched to andecaliximab administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
Receives: Biological: Andecaliximab; Biological: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. For Cohort 1, Percentage of Participants With EBS Clinical Remission at Week 8

    EBS clinical remission was defined as an endoscopic subscore of 0 or 1 (endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]); rectal bleeding subscore of 0 (rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes); and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1 (stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal).

    Measured: Week 8

Secondary outcomes (6)
  1. For Cohort 1, Percentage of Participants With MCS Remission at Week 8

    The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. The MCS remission was defined as a MCS of ≤ 2 points and no individual subscore > 1 point. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening.

    Measured: Week 8

  2. For Cohort 1, Percentage of Participants With MCS Response at Week 8

    The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening. The MCS response was defined as a MCS reduction of ≥ 3 points and at least 30% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of 0 or 1.

    Measured: Week 8

  3. For Cohort 1, Percentage of Participants With Endoscopic Remission at Week 8

    Endoscopic remission was defined as endoscopic subscore of 0. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).

    Measured: Week 8

  4. For Cohort 1, Percentage of Participants With Endoscopic Response at Week 8

    Endoscopic response was defined as endoscopic subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).

    Measured: Week 8

  5. For Cohort 1, Percentage of Participants With Mucosal Healing as Determined by the Geboes Histologic Scoring System at Week 8

    Mucosal healing was defined as elimination of ulcers/erosion, elimination of crypt destruction, elimination of intraepithelial neutrophils, elimination of lamina propria neutrophils, and reduction in lamina propria chronic inflammatory cells to at most a mild increase. When measured by the Geboes histologic scoring system, it was the selection of the following combined scores of ≤ 3 for Grade 0 (Structural Architectural Change), ≤ 1 for Grade 1 (Chronic Inflammatory Infiltrate), ≤ 3 for Grade 2A (Lamina Propria Eosinophils), and 0 for Grade 2B (Lamina Propria Neutrophils), Grade 3 (Neutrophils in Epithelium), Grade 4 (Crypt Destruction), and Grade 5 (Erosion or Ulceration). Total Geboes histologic score ranged from 0 to 22, with higher scores indicating greater disease severity.

    Measured: Week 8

  6. For Cohort 1, Percentage of Participants With MCS Remission (Alternative Definition) at Week 8

    The MCS remission (alternative definition) was defined as a rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA subscore (range: 0 to 3 with higher score indicating the severe disease) of 0, and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]) of 0 or 1 for an overall MCS of ≤ 1. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening.

    Measured: Week 8

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Aug 2015 (estimated)
  2. Study startSep 2015
  3. Primary completionSep 2016
  4. Study completionNov 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
165 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02520284
Sponsor's protocol ID
GS-US-326-1100
Other IDs
2014-005217-24, 2014
Status last verified
Mar 2019
First submitted
7 Aug 2015
Last updated
10 Apr 2019
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Andecaliximab in people with Ulcerative Colitis, run by Gilead Sciences at 87 sites in 23 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 10 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 87 sites in United States, Poland, Ukraine, Australia, Russia and 18 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 Apr 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

For Cohort 1, Percentage of Participants With EBS Clinical Remission at Week 8 (time frame: Week 8). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in